Skip to content
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Positron Corp. POSC

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$461,452
▼ 21.5% YoY
$-10.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Positron is a medical technology company that co-develops, manufactures and sells PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. Positron Corporation is a medical technology company focused on advancing positron emission tomography (“PET”) imaging through the development, manufacture, and commercialization of PET and PET-computed tomography (“PET-CT”) imaging systems. The Company maintains a primary focus on cardiac PET imaging, which is widely utilized in nuclear cardiology for the diagnosis and management of cardiovascular disease. The Company’s PET and PET-CT imaging systems are co-manufactured through its partner, Neusoft Medical Systems, at its development and manufacturing facilities in Shenyang, China, including through affiliated entities. As of the date of this filing, the Company employed 10 full-time employees. Positron’s Headquarters is in North Tonawanda, NY.

Written from the business description in Positron Corporation's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

USD 461,452.00
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.5 · Net income -10.6
2.5M5.0M-5.0M-10.0M
201020132025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -2275.1% · Net ·
-1000%-2000%
201020132025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2014 · FCF -2.4
-2M-4M
201020132025

Total assetsUSD 4.0M
EquityUSD 1.4M
Gross debtUSD 153,686.00
DepositsUSD 375,000.00
Current ratio1.39×

Equity funds 36% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
POSC, 7-year financial record
Metric 2025202420142013201220112010
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0◌◌◌◌◌
Income tax $B◌◌0.00.00.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.34−0.090.000.00−0.01−0.01−0.02
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE % — not applicable: negative equity———————
Shares out B0.030.035.551.451.450.790.78

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 32 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image